A novel mitochondrial DNA deletion in a patient with Kearns-Sayre syndrome: a late-onset of the fatal cardiac conduction deficit and cardiomyopathy accompanying long-term rGH treatment

Table 1 Selected parameters during rGH therapy

	Age [years]	Height SDS	Bone age [G&P] [years]	Height velocity [cm/year]	Predicted adult height based on Bayley-Pinneau method [cm]	rGH Dose [mg/kg/24 h]
the beginning of rGH therapy	12	−3.5	10	8.5	161.9	0.024
after 6 months of rGH therapy	12 6/12	−2.9	11	10.5	164.6	0.024
after 12 months of rGH therapy	13	−2.6	13	7.5	161.7	0.024
after 2 years of rGH therapy	14 3/12	−2.2	13 6/12	10.0	168.5	0.022
after 3 years of rGH therapy	15 2/12	−2.3	14 6/12	4.5	168.5	0.018
after 4 years of rGH therapy	16	−2.3	15	2.5	166.5	0.018
after 5 years of rGH therapy	17	−2.6	16	1.3	166	Discontinuation of treatment

ISSN: 1471-2431